ALLR
Allarity Therapeutics Inc (ALLR)
Healthcare • NASDAQ • $0.90+7.48%
- Symbol
- ALLR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.90
- Daily Change
- +7.48%
- Market Cap
- $14.24M
- Trailing P/E
- N/A
- Forward P/E
- -1.04
- 52W High
- $1.84
- 52W Low
- $0.77
- Analyst Target
- $11.00
- Dividend Yield
- 0.00%
- Beta
- 0.57
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer…
Company websiteResearch ALLR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.